BC Platforms, founded in 1997 from an MIT Whitehead project spinoff, is in the business of powerful genomic data management and analysis solutions. The company operates a global network of biobanks known as BCRQUEST.COM, which provides genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development in Helsinki, Finland, and sales and marketing in London, Boston, and Vancouver.
Negen is a genetic technology company founded in Finland by geneticists and physicians. Amongst others, it provides services to biobanks. By returning genetic health data to donors, Ngen not only serves existing benefactors, but also increases the interest of potential new donors.
Negen provides tools to prevent common chronic diseases, such as type 2 diabetes and coronary heart disease based on genetic profiling combined with commonly known measurable risk factors. Using the company’s automatized process algorithms, an individual predisposition for a disease can be assessed with the highest accuracy available today in easily understandable and human readable format.
This information is proven to help individuals to re-evaluate individual lifestyle choices and help physicians to adjust the care or treatment path for successful disease prevention and cost savings in health care.
BC Platforms has signed a co-operation agreement with Negen to use its platform to provide detailed insights into raw genomic data for clinical reporting capabilities. Incoming data will be processed by BC Platforms’ high performing genomic data management platform allowing rapid integration to the highly rated Genetic Risk Scoring tools developed by Negen.
“We are delighted to partner with BC Platforms, a global leader in the integration and interpretation of genomic and clinical data. This partnership will greatly increase the awareness and utility of our Genetic Risk Scoring tools and our automatized genetic data interpretation. We look forward to bringing the benefits to both clinicians and patients,” – Kimmo Aro, CEO of Negen.
“With the increased adoption of precision medicine, … We are pleased to partner with Negen to add this downstream capability to our platform,” – Tero Silvola, the CEO of BC Platforms.